Axsome Therapeutics, Inc.

AXSM · NASDAQ

AXSM has an annual revenue baseline of $638.5M, latest revenue marker of $191.2M Q1 2026, annual net income of -$183.2M and cash of $305.1M. The thesis depends on revenue durability, margins, cash conversion and balance-sheet discipline.

Follow Add to Watchlist Ask Question

NASDAQ AXSM Coverage Bootstrap Nasdaq Axsome Therapeutics, Inc.

Latest ReportMay 20, 2026Axsome Therapeutics: the neuroscience growth story still has to outrun losses and cash burnView report ->Total Reports1Published reportView all ->Active Discussions0No visible comments yetView discussions ->Member WorkspaceLockedFinancials, timeline, comparisons, scorecard, and discussion require a paid login.View access ->

Company filters1 of 1 reports match

Clear filters

Add tags

Selected tags

AXSM

Clear tags

Latest Thesis

Axsome Therapeutics: the neuroscience growth story still has to outrun losses and cash burn

May 20, 2026Research reportSlides available

Read report Open slides Discussion (0)

Axsome Therapeutics, Inc.Therapeutics: the neuroscience growth story still has to outrun May 20, 2026

Member workspace

Financials and workspace tools are for paid members.

Paid login unlocks company financials, filing timeline, peer comparison, scorecard, and discussion. Valuation remains admin-only while we finalize market-data licensing.

Recent Reports

Compact report index for this company.

View all 1 reports ->

ReportTypeUpdatedReadActions

Axsome Therapeutics: the neuroscience growth story still has to outrun losses and cash burnAXSM has an annual revenue baseline of $638.5M, latest revenue marker of $191.2M Q1 2026, annual net income of -$183.2M and cash of $305.1M. The thesis depends on revenue durability, margins, cash conversion and balance-sheet discipline.NASDAQMay 20, 2026Research reportRead Slides